Abstract 215P
Background
mnccRCC had a poor response to VEGF-targeted tyrosine kinase inhibitors (TKIs) and the first-line therapy was still limited. Our real-world study aimed to evaluate the effectiveness of tislelizumab-axitinib combination therapy versus TKI monotherapy as the first-line regimen in patients (pts) with mnccRCC.
Methods
Pts with mnccRCC received first-line therapy were identified between Jul. 2019 and Dec. 2022 in Sun Yat-sen University Cancer Center. Pts received first-line TKI monotherapy (TKI group, mainly sunitinib) or tislelizumab plus axitinib therapy (T+A group). Baseline characteristics, objective response rate (ORR), progression-free survival (PFS), PFS2 (defined as time from initial treatment to progression after first subsequent therapy or any-cause death.) and overall survival (OS) were retrospectively collected. The differences on effectiveness between the two groups were compared.
Results
Totally 39 pts were included, with a median age of 46 (17-72) years. 77.1% had an IMDC intermediate/poor-risk disease. 53.8% had papillary RCC, 19.5% had Mit family translocation RCC, 12.1% had chromophobe RCC and others had unclassified RCC. The median follow-up was 23.7 (18.5-29.0) months. The T+A group (n=20) had a significantly longer PFS compared with the TKI group(n=19) (median PFS (95% CI): 11.0 (8.1-14.0) vs 4.6 (3.0-6.2) months, P<0.001). Similarly, ORR was remarkably improved in the T+A group (40.0% vs 10.5%, P=0.006). The PFS2 did not come to the significant difference between the T+A group and TKI group (median PFS2 (95% CI): 18.6 (NR-NR) vs 12.0 (7.9-16.2) months, P=0.646). Median OS was not reached for T+A group and TKI group (median OS (95% CI): NR vs 39.6 (NR-NR) months, P= 0.176).
Conclusions
Tislelizumab plus axitinib could be an effective first-line regimen option for mnccRCC pts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sun Yat-sen University Cancer Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
16P - Patient and healthcare practitioner preferences in early-stage triple-negative breast cancer treatment: A discrete choice experiment
Presenter: Jiun-I Lai
Session: Poster Display
Resources:
Abstract
17P - Initial outcomes of the ACT Now PRIME CARE for breast cancer: Prevention of Breast canceR (screening/ stage shifting) utilizing Integrated MobilE Clinics and pAtient Reported online Evaluations and Education
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
18P - Optimizing premenopausal HR+ HER2–ve eBC management in India: Insights from expert consensus
Presenter: Anitha Ramesh
Session: Poster Display
Resources:
Abstract
19P - Referral patterns among breast cancer patients in county-level hospitals in China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
20P - Real-world treatment of HER2+ and HR+/HER2- early breast cancer in county areas of China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
21P - Duration of breast cancer trials: Analysis of predicted versus actual completion date
Presenter: Daniëlle Verschoor
Session: Poster Display
Resources:
Abstract
22P - Impact of an online Asian genetic risk calculator on risk perception: Cancer-related distress and uptake of genetic counselling among Malaysian breast cancer patients (The ARiCa Study)
Presenter: HEAMANTHAA Padmanabhan
Session: Poster Display
Resources:
Abstract
23P - Consensus statements and expert recommendations for BRCAm breast cancer in the Asia-Pacific region (STREAM-AP)
Presenter: Soo Chin Lee
Session: Poster Display
Resources:
Abstract
24P - Germline genetic testing for hereditary cancer: A retrospective analysis in a single site referral centre in Malaysia
Presenter: Vivian Lee
Session: Poster Display
Resources:
Abstract
25P - Clinical presentations and prognostication of HER2-low breast cancer in Taiwan
Presenter: Bo-Fang Chen
Session: Poster Display
Resources:
Abstract